US-based SynCardia Systems, LLC., a global leader in total artificial heart technology, has announced that the China National Intellectual Property Administration has granted a patent for its next-generation total artificial heart, Emperor. This patent covers novel technology designed to eliminate external drive mechanisms by fully integrating the pumping mechanism within the implanted artificial heart ventricle.
Patent Details
The patent was authorized in the US in March 2024 (NO. 11,918,797), with the total artificial heart winning additional patent protection in October of the same year (NO. 12,121,711 B2). The next-generation Emperor artificial heart design builds upon SynCardia’s proven technology, with innovations aimed at improving patient outcomes and expanding accessibility to life-saving cardiac support.
Significance of the Patent
This patent approval in China marks a significant milestone for SynCardia, further solidifying its position as a leader in artificial heart technology. The Emperor artificial heart represents a major advancement, offering a more integrated and efficient solution for patients in need of cardiac support.
Company Background
SynCardia’s total artificial heart is the only artificial heart approved in both the US and Canada, and it has been applied in over 2100 patients worldwide. This widespread use underscores the reliability and effectiveness of SynCardia’s technology in providing critical cardiac support.-Fineline Info & Tech
